Skip to Main content Skip to Navigation
Journal articles

Dacarbazine mediate antimelanoma effects via NK cells.

Abstract : Melanoma is a highly chemoresistant and metastatic tumor that, in the absence of BRAF mutations, is generally treated with the alkylating agent dacarbazine (DTIC). We discovered that DTIC upregulates the expression of NKG2D ligands on tumor cells, leading to the activation of natural killer (NK) and CD8(+) T cells. These observations underscore the immunogenic properties of DTIC and provide a rationale to combine DTIC with immunotherapeutic agents.
Document type :
Journal articles
Complete list of metadata

Cited literature [10 references]  Display  Hide  Download
Contributor : Grégoire Mignot Connect in order to contact the contributor
Submitted on : Wednesday, September 4, 2013 - 10:48:04 AM
Last modification on : Tuesday, October 19, 2021 - 11:05:38 AM
Long-term archiving on: : Thursday, April 6, 2017 - 3:18:54 PM


 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : jamais

Please log in to resquest access to the document




Alice Hervieu, Gregoire Mignot, François Ghiringhelli. Dacarbazine mediate antimelanoma effects via NK cells.. OncoImmunology, Taylor & Francis, 2013, 2 (4), pp.e23714. ⟨10.4161/onci.23714⟩. ⟨inserm-00857884⟩



Record views